hydralazine has been researched along with Lung Neoplasms in 13 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A549 (lung cancer) and U373MG (glioblastoma) cells were exposed to radiation with or without six DNMT inhibitors (5-azacytidine, 5-aza-2'-deoxycytidine, zebularine, hydralazine, epigallocatechin gallate, and psammaplin A) for 18 hours prior to radiation, after which cell survival was evaluated via clonogenic assays." | 3.78 | DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity. ( Chie, EK; Kim, HJ; Kim, IA; Kim, IH; Kim, JH; Young, PD, 2012) |
| "The effects of the two vasodilating substances, dihydralazine and the adrenergic alpha-receptor blocker phenoxybenzamine, were studied on the distribution and growth of MCG-L-SS metastases from intravenously injected tumour cells." | 3.65 | Alteration of metastases distribution by vaso-dilating drugs. ( Boeryd, B; Hagmar, B; Johnsson, G; Ryd, W, 1975) |
| "Hydralazine has been shown to reduce tumour blood flow and to potentiate the cytotoxicity of melphalan and bioreductive agents in mice." | 1.28 | The effects of single dose oral hydralazine on blood flow through human lung tumours. ( Cronin, B; Flower, MA; Horwich, A; McCready, VR; Rowell, NP, 1990) |
| " Such reduced tumor oxygenation would increase the cytotoxic effects of RSU-1069 which is known to be more toxic to cells at reduced oxygen levels." | 1.27 | The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain. ( Acker, B; Chaplin, DJ, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (61.54) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carter, CA | 1 |
| Zeman, K | 1 |
| Day, RM | 1 |
| Richard, P | 1 |
| Oronsky, A | 1 |
| Oronsky, N | 1 |
| Lybeck, M | 1 |
| Scicinski, J | 1 |
| Oronsky, B | 1 |
| Kim, HJ | 1 |
| Kim, JH | 1 |
| Chie, EK | 1 |
| Young, PD | 1 |
| Kim, IA | 1 |
| Kim, IH | 1 |
| PERRY, HM | 1 |
| Duster, T | 1 |
| Toth, B | 1 |
| Boeryd, B | 1 |
| Hagmar, B | 1 |
| Johnsson, G | 1 |
| Ryd, W | 1 |
| Rowell, NP | 2 |
| Flower, MA | 1 |
| McCready, VR | 1 |
| Cronin, B | 1 |
| Horwich, A | 1 |
| Clark, K | 1 |
| Chaplin, DJ | 3 |
| Acker, BD | 1 |
| Horsman, MR | 1 |
| Kaufman, DW | 1 |
| Kelly, JP | 1 |
| Rosenberg, L | 1 |
| Stolley, PD | 1 |
| Warshauer, ME | 1 |
| Shapiro, S | 1 |
| Acker, B | 1 |
| Drozdz, M | 1 |
| Luciak, M | 1 |
| Jendryczko, A | 1 |
| Magner, K | 1 |
2 reviews available for hydralazine and Lung Neoplasms
| Article | Year |
|---|---|
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.
Topics: Antibodies, Monoclonal; Azacitidine; Azetidines; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small | 2016 |
Medicalisation of race.
Topics: Age Distribution; Aged; Antineoplastic Agents; Black or African American; Clinical Trials as Topic; | 2007 |
11 other studies available for hydralazine and Lung Neoplasms
| Article | Year |
|---|---|
DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity.
Topics: Azacitidine; Caspase 3; Catechin; Cell Line, Tumor; Cytidine; Decitabine; Disulfides; DNA (Cytosine- | 2012 |
CARCINOMA AND HYDRALAZINE TOXICITY IN PATIENTS WITH MALIGNANT HYPERTENSION.
Topics: Breast Neoplasms; Carcinoma; Humans; Hydralazine; Hypertension; Hypertension, Malignant; Lung Neopla | 1963 |
Tumorigenic effect of 1-hydrazinophthalazine hydrochloride in mice.
Topics: Adenocarcinoma; Adenoma; Animals; Female; Humans; Hydralazine; Lung Neoplasms; Male; Mice; Neoplasms | 1978 |
Alteration of metastases distribution by vaso-dilating drugs.
Topics: Animals; Dihydralazine; Hydralazine; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Inbred CBA; Neopla | 1975 |
The effects of single dose oral hydralazine on blood flow through human lung tumours.
Topics: Administration, Oral; Aged; Carcinoma, Bronchogenic; Dose-Response Relationship, Drug; Female; Human | 1990 |
The effects of oral hydralazine on blood pressure, cardiac output and peripheral resistance with respect to dose, age and acetylator status.
Topics: Acetylation; Administration, Oral; Age Factors; Aged; Blood Pressure; Carcinoma, Bronchogenic; Cardi | 1990 |
Reduction of tumour blood flow by vasoactive drugs: a role in cancer therapy.
Topics: Animals; Cell Survival; Chlorambucil; Hydralazine; Hyperthermia, Induced; Lung Neoplasms; Mammary Ne | 1989 |
Hydralazine use in relation to cancers of the lung, colon, and rectum.
Topics: Adult; Aged; Colonic Neoplasms; Female; Humans; Hydralazine; Lung Neoplasms; Male; Middle Aged; Rect | 1989 |
Postirradiation modification of tumor blood flow: a method to increase the effectiveness of chemical radiosensitizers.
Topics: Animals; Cell Survival; Combined Modality Therapy; Female; Hydralazine; Lung Neoplasms; Mice; Mice, | 1988 |
The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain.
Topics: Animals; Cell Survival; Cells, Cultured; Female; Hydralazine; Lung Neoplasms; Mice; Mice, Inbred C57 | 1987 |
Changes in lung activity of superoxide dismutase and copper concentration during lung tumorigenesis by hydralazine in Swiss mice.
Topics: Adenocarcinoma; Adenoma; Animals; Carcinogens; Copper; Hydralazine; Lung; Lung Neoplasms; Mice; Sex | 1987 |